Dyne Therapeutics, Inc.

NASDAQ: DYN · Healthcare · Biotechnology

PublicHQ Waltham, MA · MiddlesexCIK 0001818794Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 56DQ —GM —SS 65

v0.1 · 35/100 weight · pillars only

↑ market scale, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$446.2M

Employees

258

as of 2026-08-07

Market cap

$4.8B

as of 2026-08-07

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$446.2M-$446.2M2025

Operating income-$468.2M-$468.2M2025

Total assets$1.2B$1.2B2025

Liabilities$214.8M$214.8M2025

Equity$972.1M$972.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Dyne Therapeutics, Inc.’s financial profile?

Dyne Therapeutics, Inc. earned -$446.2M in FY2025 net income.

Peers · Healthcare

Belite Bio, Inc——Erasca, Inc.——Definium Therapeutics, Inc.——Edgewise Therapeutics, Inc.——Celcuity Inc.——Veradermics, Incorporated——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B49D

Key facts

CEOJohn G. Cox

SectorHealthcare

IndustryBiotechnology

HeadquartersWaltham, MA

ExchangeNASDAQ: DYN

Employees258

IPO date2020-09-17

Latest filings

10-Q2026-07-29 8-K2026-07-29 8-K2026-07-22 8-K2026-07-20 8-K2026-06-22 8-K2026-06-17 8-K2026-06-08 8-K2026-06-03

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.